title: Long-acting repeatable bromocriptine in the treatment of patients with microprolactinoma intolerant or resistant to oral dopaminergics.
abstract: OBJECTIVE
  To study the efficacy of long-acting repeatable bromocriptine in suppressing abnormal PRL secretion in microprolactinoma patients. To assess the incidence and nature of side effects induced by the product.
  
  
  METHODS
  Longitudinal, open label, noncontrolled.
  
  
  METHODS
  Human hyperprolactinemic volunteers in an academic clinical research environment.
  
  
  METHODS
  Ten patients with radiologically proven microademonas resistant or intolerant to oral bromocriptine were included.
  
  
  METHODS
  The patients were treated with 50 to 150 mg of long-acting bromocriptine monthly during 6 months.
  
  
  METHODS
  The serum PRL concentrations and the side-effects were assessed before and after each new injection.
  
  
  RESULTS
  Serum PRL levels decreased during the first cycle to normal values in four patients. At the end of the study the PRL levels were normalized in five cases and were only slightly increased in three. One patient was resistant to the treatment. Two among four infertile women became pregnant. In nine patients the accompanying symptoms disappeared after the 2nd month. Adverse events were mild or moderate and circumscribed to the 1st month of treatment.
  
  
  CONCLUSIONS
  The long-acting bromocriptine is both effective and well tolerated and is a good alternative to the oral approach in the management of microprolactinoma patients.
authors.affiliation: Santa Creu i Sant Pau Hospital, Universitat Autonoma, Barcelona, Spain.
authors.forename: J J
authors.initials: JJ
authors.lastname: Espinós
authors.forename: J
authors.initials: J
authors.lastname: Rodríguez-Espinosa
authors.forename: S M
authors.initials: SM
authors.lastname: Webb
authors.forename: J
authors.initials: J
authors.lastname: Calaf-Alsina
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D015259:Dopamine Agents / Q000008:administration & dosage*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008137:Longitudinal Studies; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000188:drug therapy*
chemical_list: D003692:Delayed-Action Preparations; D015259:Dopamine Agents; D001971:Bromocriptine; D011388:Prolactin